Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GP vs GC in advanced TNBC
NCT02341911Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Jan 2015
- Primary completion
- Dec 2022
- Modality
- Nanoparticles, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gemcitabine, Cisplatin micelle injection (HA132) and carboplatin in triple negative breast cancer (TNBC), sponsored by Fudan University. Primary endpoint: Progression-Free Survival at 6 weeks. Status: unknown.
02
Drugs
gemcitabineCisplatin micelle injection (HA132)carboplatin
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02341911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02341911.